Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC.ACTU · Entity 7370 | Director | May 21, 2026 | May 22, 2026 |
| BlossomHill Therapeutics, Inc.BLSM · Entity 5423 | Chief Financial Officer | August 06, 2026 | August 10, 2026 |
| Carisma Therapeutics Inc.SESN · Entity 74418 | Director | June 22, 2022 | June 24, 2022 |
| Equillium, Inc.EQ · Entity 6560 | Chief Financial Officer | February 14, 2025 | February 20, 2025 |
| Orexigen Therapeutics, Inc.OREX · Entity 157016 | EVP, Chief Financial Officer | October 13, 2017 | October 17, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACTUATE THERAPEUTICS, INC.
Report date May 21, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.42 · Expires 2036-05-21 | Direct | 15,000 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 15,000 · Balance 15,000 F1: Options will vest in full on the anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options will vest in full on the anniversary of the grant date.
BlossomHill Therapeutics, Inc.
Report date August 06, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 700 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Purchase · Acquired 700 · Balance 700 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-08-05 | Direct | 56,746 |
Reported balance
After 2026-08-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-06 · Grant · Acquired 56,746 · Balance 56,746 F1: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months.
Carisma Therapeutics Inc.
Report date June 22, 2022 · Filed June 24, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,000 |
Reported balance
After 2022-06-22 transaction · row 1
1 source rowRow 1 · 2022-06-22 · Grant · Acquired 40,000 · Balance 40,000 F1: Represents restricted stock units ("RSUs") which shall vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Sesen Bio, Inc. common stock. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2032-06-22 | Direct | 65,000 |
Reported balance
After 2022-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-22 · Grant · Acquired 65,000 · Balance 65,000 F2: The option was granted on June 22, 2022 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") which shall vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Sesen Bio, Inc. common stock.
F2: The option was granted on June 22, 2022 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested.
Equillium, Inc.
Report date February 14, 2025 · Filed February 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2029-02-12 | Direct | 70,000 |
Reported balance
After 2025-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-14 · Grant · Acquired 70,000 · Balance 70,000 F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.45 · Expires 2029-02-12 | Direct | 0 |
Reported balance
After 2025-02-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-14 · Disposition to issuer · Disposed 70,000 · Balance 0 F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2029-12-09 | Direct | 90,000 |
Reported balance
After 2025-02-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-14 · Grant · Acquired 90,000 · Balance 90,000 F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.45 · Expires 2029-12-09 | Direct | 0 |
Reported balance
After 2025-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-14 · Disposition to issuer · Disposed 90,000 · Balance 0 F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2031-01-03 | Direct | 100,000 |
Reported balance
After 2025-02-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-14 · Grant · Acquired 100,000 · Balance 100,000 F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.03 · Expires 2031-01-03 | Direct | 0 |
Reported balance
After 2025-02-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-14 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2032-01-18 | Direct | 125,000 |
Reported balance
After 2025-02-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-02-14 · Grant · Acquired 125,000 · Balance 125,000 F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.86 · Expires 2032-01-18 | Direct | 0 |
Reported balance
After 2025-02-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-02-14 · Disposition to issuer · Disposed 125,000 · Balance 0 F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.79 · Expires 2033-01-02 | Direct | 175,000 |
Reported balance
After 2025-02-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-02-14 · Grant · Acquired 175,000 · Balance 175,000 F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2033-01-02 | Direct | 0 |
Reported balance
After 2025-02-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-02-14 · Disposition to issuer · Disposed 175,000 · Balance 0 F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.
F2: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged.
Orexigen Therapeutics, Inc.
Report date October 13, 2017 · Filed October 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security | Direct | 69,600 |
Reported balance
After 2017-10-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-13 · Grant · Acquired 69,600 · Balance 69,600 F1: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement. F2: Reflects an award of restricted stock units ("RSUs"), each representing a contingent right to receive a share of the issuer's common stock upon settlement. F3: Twenty-five percent (25%) of the RSUs will vest on each of the first four (4) anniversaries of February 3, 2018 (each, a "Vesting Date"), subject to the reporting person's continued eligibility on each applicable Vesting Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
F2: Reflects an award of restricted stock units ("RSUs"), each representing a contingent right to receive a share of the issuer's common stock upon settlement.
F3: Twenty-five percent (25%) of the RSUs will vest on each of the first four (4) anniversaries of February 3, 2018 (each, a "Vesting Date"), subject to the reporting person's continued eligibility on each applicable Vesting Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 10, 2026 22:27 UTC | BlossomHill Therapeutics, Inc. BLSM · Entity 5423 | PurchaseCommon Stock | 700 | $16.00 | $11,200.00 |
DisclosureSEC source: 0001678152-26-000003 · form4-08102026_100815.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700 Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 22:27 UTC | BlossomHill Therapeutics, Inc. BLSM · Entity 5423 | GrantEmployee Stock Option (Right to Buy) · Derivative | 56,746 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001678152-26-000003 · form4-08102026_100815.xml · derivative · entry 2 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,746 Underlying: Common Stock · 56,746 shares Expires 2036-08-05 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on August 6, 2027, and the balance of the shares shall vest in equal monthly installments over the following 36 months. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:04 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantStock Options · Derivative | 15,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001683168-26-004245 · ownership.xml · derivative · entry 1 Keyes Jason A · CIK 0001678152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-05-21 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:05 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantStock Options · Derivative | 15,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001683168-25-003992 · ownership.xml · derivative · entry 1 Keyes Jason A · CIK 0001678152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-05-22 F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:33 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 175,000 | Not disclosed Strike: $1.06 | Not disclosed |
DisclosureSEC source: 0001415889-25-004756 · form4-02202025_120235.xml · derivative · entry 10 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,000 shares Expires 2033-01-02 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:33 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004756 · form4-02202025_120235.xml · derivative · entry 9 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-01-02 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:33 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 125,000 | Not disclosed Strike: $3.86 | Not disclosed |
DisclosureSEC source: 0001415889-25-004756 · form4-02202025_120235.xml · derivative · entry 8 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2032-01-18 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:33 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004756 · form4-02202025_120235.xml · derivative · entry 7 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-18 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:33 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $5.03 | Not disclosed |
DisclosureSEC source: 0001415889-25-004756 · form4-02202025_120235.xml · derivative · entry 6 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2031-01-03 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:33 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004756 · form4-02202025_120235.xml · derivative · entry 5 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-01-03 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:33 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001415889-25-004756 · form4-02202025_120235.xml · derivative · entry 4 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2029-12-09 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:33 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004756 · form4-02202025_120235.xml · derivative · entry 3 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-12-09 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:33 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 70,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001415889-25-004756 · form4-02202025_120235.xml · derivative · entry 2 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2029-02-12 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:33 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 70,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004756 · form4-02202025_120235.xml · derivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-12 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 23:37 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 10,000 | $0.65 | $6,500.00 |
DisclosureSEC source: 0001415889-25-002070 · form4-01242025_110117.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 37,720 F1 · kind: The transactions reported on this form were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.62 to $0.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:11 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001415889-25-000843 · form4-01062025_110147.xml · derivative · entry 3 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2035-01-01 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| December 10, 2024 Filed Jan 6, 2025 23:11 UTC | Equillium, Inc. EQ · Entity 6560 | GrantCommon Stock | 15,000 | $0.54 | $8,100.00 |
DisclosureSEC source: 0001415889-25-000843 · form4-01062025_110147.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,913 F1 · kind: These shares were acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 14, 2024 Filed Nov 15, 2024 23:23 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 10,000 | $0.70 | $7,000.00 |
DisclosureSEC source: 0001415889-24-026987 · form4-11152024_111115.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 47,720 F1 · kind: The transactions reported on this form were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.67 to $0.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 26, 2024 Filed Sep 27, 2024 23:38 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 10,000 | $0.81 | $8,100.00 |
DisclosureSEC source: 0001415889-24-024079 · form4-09272024_110919.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 57,720 F1 · kind: The transactions reported on this form were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.79 to $0.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 23:27 UTC | ACTUATE THERAPEUTICS, INC. ACTU · Entity 7370 | GrantNon-Qualified Stock Options · Derivative | 30,000 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001104659-24-089793 · tm2421559-3_4seq1.xml · derivative · entry 1 Keyes Jason A · CIK 0001678152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-08-12 F1 · derivative.exercise_date: 30,000 stock options granted upon the effectiveness of the registration statement for the issuer's initial public offering on August 12, 2024, which vest in three equal installments on the first, second, and third anniversary of the grant date, subject to the reporting person's continued service through each such vesting date. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:52 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 10,000 | $0.87 | $8,700.00 |
DisclosureSEC source: 0001415889-24-019776 · form4-07182024_090731.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 67,720 F1 · kind: The transactions reported on this form were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9342, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 23:10 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-24-000515 · doc4.xml · derivative · entry 4 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| December 08, 2023 Filed Jan 3, 2024 23:10 UTC | Equillium, Inc. EQ · Entity 6560 | GrantCommon Stock | 8,805 | $0.58 | $5,106.90 |
DisclosureSEC source: 0001209191-24-000515 · doc4.xml · nonDerivative · entry 2 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,913 F1 · kind: These shares were acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 09, 2023 Filed Jan 3, 2024 23:10 UTC | Equillium, Inc. EQ · Entity 6560 | GrantCommon Stock | 15,000 | $0.56 | $8,400.00 |
DisclosureSEC source: 0001209191-24-000515 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,108 F1 · kind: These shares were acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:50 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-001367 · doc4.xml · derivative · entry 3 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-01-02 F2 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| December 09, 2022 Filed Jan 4, 2023 23:50 UTC | Equillium, Inc. EQ · Entity 6560 | GrantCommon Stock | 4,444 | $1.19 | $5,288.36 |
DisclosureSEC source: 0001209191-23-001367 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,108 F1 · kind: These shares were acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 29, 2022 Filed Aug 30, 2022 21:57 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 7,000 | $2.83 | $19,810.00 |
DisclosureSEC source: 0001209191-22-048037 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 77,720 F1 · kind: The transactions reported on this form were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.80 to $2.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 18:29 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 65,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001485003-22-000082 · wf-form4_165610974251502.xml · derivative · entry 2 Keyes Jason A · CIK 0001678152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2032-06-22 F2 · derivative.exercise_date: The option was granted on June 22, 2022 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 18:29 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001485003-22-000082 · wf-form4_165610974251502.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · shares: Represents restricted stock units ("RSUs") which shall vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Sesen Bio, Inc. common stock. Read SEC document |
| June 06, 2022 Filed Jun 7, 2022 01:17 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 5,000 | $2.52 | $12,600.00 |
DisclosureSEC source: 0001209191-22-034749 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 84,720 F1 · kind: The transactions reported on this form were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.48 to $2.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 21:40 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 8,000 | $3.18 | $25,440.00 |
DisclosureSEC source: 0001209191-22-023220 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 89,720 F1 · kind: The transactions reported on this form were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.12 to $3.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 19, 2022 Filed Feb 7, 2023 23:45 UTC | Equillium, Inc. EQ · Entity 6560 | GrantEmployee Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.86 | $0.00 |
DisclosureSEC source: 0001209191-23-007678 · doc4.xml · derivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-01-18 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 15:01 UTC | Equillium, Inc. EQ · Entity 6560 | GrantCommon Stock | 5,585 | $2.35 | $13,124.75 |
DisclosureSEC source: 0001209191-21-069177 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,296 F1 · kind: The shares were acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 18:57 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 5,000 | $5.08 | $25,401.50 |
DisclosureSEC source: 0001209191-21-067752 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 97,720 F1 · shares: The transactions reported on this form were effected pursuant to a 10b5-1 trading plan adopted by the filer on August 26, 2020. F2 · price: Volume Weighted Average price of $5.0803. The range of sales prices on the transaction date was $4.750 - $5.320 per share. The reporting person undertakes to provide, upon request of the SEC Staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 17:02 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 8,000 | $6.74 | $53,924.00 |
DisclosureSEC source: 0001209191-21-058029 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 102,720 F1 · shares: The transactions reported on this form were effected pursuant to a 10b5-1 trading plan adopted by the filer on August 26, 2020. F2 · price: Volume Weighted Average price of $6.7405. The range of sales prices on the transaction date was $6.58 - $6.88, per share. The reporting person undertakes to provide, upon request of the SEC Staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| July 27, 2021 Filed Jul 28, 2021 15:55 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 5,000 | $5.72 | $28,585.00 |
DisclosureSEC source: 0001209191-21-048405 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 110,720 F1 · shares: The transactions reported on this form were effected pursuant to a 10b5-1 trading plan adopted by the filer on August 26, 2020. F2 · price: Volume Weighted Average price of $5.7170. The range of sales prices on the transaction date was $5.42 - $5.93, per share. The reporting person undertakes to provide, upon request of the SEC Staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:56 UTC | Equillium, Inc. EQ · Entity 6560 | GrantCommon stock, par value $0.0001 per share | 5,535 | $2.35 | $13,007.25 |
DisclosureSEC source: 0001209191-21-040314 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,711 F1 · kind: The shares were acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(c) and Rule 16b-3(d). Read SEC document |
| May 26, 2021 Filed May 28, 2021 23:03 UTC Amendment | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 5,000 | $6.50 | $32,483.50 |
DisclosureSEC source: 0001209191-21-036674 · doc4a.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 115,720 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2020. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $6.4967. The range of sale prices on the transaction date was $6.40 to $6.59 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. Read SEC document |
| May 26, 2021 Filed May 28, 2021 22:20 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 5,000 | $6.50 | $32,483.50 |
DisclosureSEC source: 0001209191-21-036648 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 115,720 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2020. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $6.4967. The range of sale prices on the transaction date was $6.40 to $6.59 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. Read SEC document |
| May 03, 2021 Filed May 5, 2021 18:22 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 92,500 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001485003-21-000096 · wf-form4_162025333944120.xml · derivative · entry 1 Keyes Jason A · CIK 0001678152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2031-05-03 F1 · derivative.exercise_date: The option was granted on May 3, 2021 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. In April 2021, Sesen Bio, Inc.'s compensation committee, based on market analysis by Radford, recommended to the Sesen Bio, Inc. board of directors, and the board of directors approved, an increase in non-employee director equity compensation from the 50th percentile to the 75th percentile of the Radford market analysis of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion. The option granted to purchase 92,500 shares of Sesen Bio, Inc.'s common stock was equivalent to the 75th percentile of such Radford market analysis. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:00 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001209191-21-002165 · doc4.xml · derivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-01-03 F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| December 23, 2020 Filed Dec 28, 2020 14:15 UTC | Equillium, Inc. EQ · Entity 6560 | SaleCommon Stock | 8,000 | $4.74 | $37,913.60 |
DisclosureSEC source: 0001209191-20-065139 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Keyes Trust Dated September 10, 2004 Disclosed balance after: 120,720 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2020. F2 · price: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $4.7392. The range of sale prices on the transaction date was $4.68 to $4.83 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 22:00 UTC | Equillium, Inc. EQ · Entity 6560 | OtherCommon Stock | 5,362 | $2.35 | $12,600.70 |
DisclosureSEC source: 0001209191-20-062993 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,176 F1 · kind: Represents shares acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:30 UTC | Equillium, Inc. EQ · Entity 6560 | OtherCommon Stock | 5,014 | $2.41 | $12,083.74 |
DisclosureSEC source: 0001209191-20-036285 · doc4.xml · nonDerivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,814 F1 · kind: Represents shares acquired by the Reporting Person under the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| May 06, 2020 Filed May 8, 2020 17:52 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 59,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001485003-20-000056 · wf-form4_158897472649929.xml · derivative · entry 1 Keyes Jason A · CIK 0001678152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires 2030-05-06 F1 · derivative.exercise_date: The option was granted on May 6, 2020 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 21:33 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001209191-20-025659 · doc4.xml · derivative · entry 4 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2029-12-09 F3 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 21:33 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerStock Option (right to buy) · Derivative | 90,000 | Not disclosed Strike: $4.75 | Not disclosed |
DisclosureSEC source: 0001209191-20-025659 · doc4.xml · derivative · entry 3 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2029-12-09 F3 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 21:33 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 70,000 | Not disclosed Strike: $2.45 | Not disclosed |
DisclosureSEC source: 0001209191-20-025659 · doc4.xml · derivative · entry 2 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-12 F2 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 21:33 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerStock Option (right to buy) · Derivative | 70,000 | Not disclosed Strike: $7.16 | Not disclosed |
DisclosureSEC source: 0001209191-20-025659 · doc4.xml · derivative · entry 1 Keyes Jason A · CIK 0001678152 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2029-02-12 F2 · price: Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged. F1 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 17:25 UTC | Carisma Therapeutics Inc. SESN · Entity 74418 | GrantStock Option · Derivative | 118,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001485003-20-000030 · wf-form4_158275590275256.xml · derivative · entry 1 Keyes Jason A · CIK 0001678152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2030-02-24 F1 · derivative.exercise_date: The option was granted on February 24, 2020 and vests monthly in equal amounts over a three-year period following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.